Phoenix Biotechnology, Inc. (PBI)'s Focus
While the prevention and treatment of human malignant disease remains PBI's primary focus, novel, patented extracts of Nerium oleander continue to reveal promising avenues of research showing activity against certain viral and neurodegenerative diseases. We are committed to the further development and commercialization of this potentially game-changing technology as we pursue affordable, scalable and sustainable ways to meet the following unmet medical needs.
A recent 2020 publication has shown that oleandrin effectively and selectively targets human breast cancer cells without affecting normal breast epithelial cells. The selectivity is based in part on the relative content of Na,K-ATPase alpha-3 subunit as previously shown by Phoenix Biotechnology scientists.
Camargo Pharmaceutical Services, LLC offers support to Phoenix Biotechnology Inc. in the development of PBI-05204, for the treatment of various tropical diseases eligible to receive priority review vouchers.
Phoenix Biotechnology has entered the Patents For Humanity awards competition sponsored by the United States Patent & Trademark Office. The program recognizes innovators who use game-changing technology to meet global humanitarian challenges. The essay submitted by the company in support of its entry is reproduced below, in its entirety.